Janux Therapeutics is a biotechnology company developing tumor-activated immunotherapies for cancer treatment. Its research centers on precision-engineered bispecific molecules intended to activate immune responses within the tumor microenvironment, helping direct T cells toward cancer cells while limiting activity elsewhere. The company is advancing clinical development of its lead program, JANX007, for prostate cancer.
Vice President, Investor Relations & Corporate Communications - Janux Therapeutics
Lead investor relations and corporate communications at Janux Therapeutics, a biotechnology company. Shape investor engagement, market positioning, and public-company messaging around scientific and financial milestones.
Description
- Create and deliver an investor relations and corporate communications strategy that supports Janux’s mission, pipeline, business goals, and long-term value creation
- Define Janux’s corporate narrative, brand positioning, identity, and messaging architecture
- Develop relationships with institutional investors, analysts, and banking partners
- Direct investor engagement and targeting through conferences, non-deal roadshows, R&D and Analyst Days, KOL webinars, analyst meetings, and related events
- Design and implement shareholder targeting and ownership strategies
- Prepare senior leaders for investor conferences, non-deal roadshows, and other high-profile investor engagements
- Develop core messages, FAQs, Q&A materials, briefings, and response frameworks
- Oversee earnings materials, investor presentations, scripts, press releases, website copy, talking points, and executive briefing materials
- Plan communications for clinical and regulatory milestones, transactions, partnerships, and financing activities
- Maintain an integrated communications calendar and agenda
- Represent Janux externally to the investment community and media
- Assess investor sentiment, stock performance, analyst coverage and commentary, peer results, and capital-markets trends
- Monitor sell-side models against internal forecasts
- Work with Legal and Finance on public communications, disclosures, earnings materials, SEC reporting, Reg FD compliance, and material-event communications
- Deliver strategic analysis and recommendations to executive leadership and the Board
- Collaborate with Clinical, Project Management, Regulatory, HR, Finance, and Legal teams
- Manage external investor-relations and communications agencies and consultants, including scope, budgets, performance, and measurement
- Report to the Chief Corporate and Business Development Officer
- Counsel executive leadership and the Board on investor sentiment, shareholder communications, market positioning, and reputational risk
- Handle additional responsibilities as required
Requirements
- Bachelor’s degree in Finance, Biology, Communications, or a related discipline is required; an MBA, PhD, or MS is preferred
- At least 12–15 years of progressive leadership experience in investor relations and/or corporate communications within biotechnology, pharmaceuticals, or life sciences
- Extensive experience leading teams and programs
- Significant oncology experience is required
- Track record supporting innovative therapeutic platforms and complex modalities, including T-cell engagers, bispecific antibodies, CAR-T or other cell therapies, antibody-drug conjugates, or advanced biologics
- Autoimmune experience is strongly preferred
- Outstanding communication skills, with the ability to explain complex scientific and business developments through clear, persuasive narratives
- Strong command of capital markets, investor behavior, and biotechnology valuation factors
- Thorough knowledge of SEC rules, Reg FD, disclosure requirements, corporate governance, and investor-relations practices
- Established connections with healthcare and life-sciences investors, analysts, and media
- Experience with investor-relations and communications platforms, external-agency management, budgets, and performance measurement
- Comfort working in a fast-moving, science-led organization
- Ability to influence cross-functional teams and senior stakeholders, demonstrate executive presence, and advise senior leaders
- Experience establishing or substantially advancing investor-relations and corporate-communications functions, infrastructure, and practices
- Experience guiding publicly traded biotechnology companies through major clinical, regulatory, corporate-development, and financing milestones
- Excellent writing and editorial judgment for scientific, corporate, investor, media, and employee audiences
- Strong integrity and dedication to ethical conduct
- Authorization to work in the United States is required
Benefits
- Annual bonus opportunity
- Incentive stock option program
- 401(k) plan with a flat, non-elective employer contribution
- Comprehensive medical coverage with 90–100% of premiums paid by the employer
- Dental and vision coverage
- HSA, FSA, and supplemental life, disability, accident, critical-illness, and hospital-indemnity insurance
- Unlimited paid time off
- Generous holiday calendar with summer and winter company shutdowns
- Relocation support
- Stock options
- Restricted stock units
- Employee stock purchase plan
- Target bonus
- Remote work available with approval
- Travel of up to 25% for meetings or site visits